ABSTRACT CD43, the major sialoglycoprotein of human leukocytes, whose expression is defective in patients with the Wiskott-Aldrich syndrome, was down-regulated by phorbol 12-myristate 13-acetate (PMA) on granulocytes but not on lymphocytes. However, CD43 expressed on both of these leukocyte subpopulations was down-regulated after crosslinking by anti-CD43 monoclonal antibodies, a stimulation that may simulate the effect of a natural CD43 ligand. Soluble, labeled CD43 molecules were isolated from culture supernatants of both surface-iodinated granulocytes activated by PMA and lymphocytes stimulated with anti-CD43 antibodies. Thus, in this case down-regulation represents release from the cell surface into the culture medium, rather than internaliztion.
CD43 is a highly sialylated major glycoprotein expressed on the surface of lymphocytes, monocytes, and granulocytes. This molecule consists of -40% protein and 60% glycans that are predominantly 0-linked (1) (2) (3) (4) . CD43 seems to have multiple physiological function including its role in cell-cell repulsion (5) and in signal transduction pathways of activated lymphocytes (6) , monocytes (7) , and granulocytes (8) . It may also function as an adhesion molecule that interacts with intercellular adhesion molecule 1 (ICAM-1) (9) . CD43 expression is defective on T cells of patients with the WiskottAldrich syndrome (10) , an X chromosome-linked recessive immunodeficiency disorder. Affected patients are susceptible to opportunistic infections and do not respond to polysaccharide antigens, implicating defects in cytotoxic and helper T-cell functions.
Recently, a soluble galactoglycoprotein (Galgp), detected in high concentrations in human serum, has been found to have a primary structure identical to the extracellular domain of CD43 (11) ; its source has been unknown. The carbohydrate composition of Galgp was atypical of plasma proteins, suggesting that Galgp might be derived from the surface of blood cells (11) . Here CD43 is shown to be proteolytically cleaved from the surface of in vitro-stimulated leukocytes. The presence of Galgp in serum suggests that proteolytic cleavage of CD43 also takes place in vivo in response to still unknown stimuli. This mechanism of proteolytic cleavage seems to be shared among several leukocyte receptors and may regulate surface expression of a number of these molecules in vivo.
METHODS
Reagents. Phorbol 12-myristate 13-acetate (PMA), fMetLeu-Phe, C5a, Nonidet P40, 1,10-phenanthroline, NO-(ptosyl)-L-lysine chloromethyl ketone (TLCK), phosphoramidon, pepstatin A, ai-antitrypsin, and N-methoxysuccinyl-AlaAla-Pro-Val chloromethyl ketone were purchased from Sigma. Recombinant human tumor necrosis factor a (TNF-a) was obtained from Promega, Ficoll-Paque was purchased from Pharmacia LKB, verografm was from Spofa (Prague), Pefabloc SC was purchased from Pentafarm (Basel), and
[125I]NaI was from NEN. Recombinant human granulocytemacrophage colony-stimulating factor (GM-CSF) was kindly provided by Sandoz Forschungsinstitut (Vienna). RPMI 1640 medium containing 10%6 (vol/vol) fetal calf serum, 2 mM glutamine, penicillin (50 units/ml), and streptomycin (50 pg/ ml) was used for cell culture.
Antibodies. The reactivities of anti-CD43 monoclonal antibody (mAb) MEM-59 (12), anti-CD45 mAbs MEM-28, -55, and -58 (13) , and IN-05 mAb recognizing human insulin (14) have been described. Anti-CD43 mAbs G10-2, G19-1, L66, and T2/53 were obtained from the Fourth International Workshop on Human Leukocyte Differentiation Antigens, Vienna, 1989 , and anti-L-selectin mAb (anti-Leu-8) was purchased from Becton Dickinson.
Isolation of Peripheral Blood Lymphocytes and Granulocytes. Lymphocytes and granulocytes were isolated from blood of healthy donors as described (15 (Fig. 1A) . In contrast, the surface expression of CD45, another molecule that is strongly expressed on these cells, remained unchanged. Treatment of granulocytes with natural soluble factors that are known to stimulate granulocytes and that are able to induce rapid down-regulation of L-selectin (21) [e.g., fMetLeu-Phe (bacterial chemotactic peptide), C5a (complement fragment), granulocyte-macrophage GM-CSF, or TNF-a] had little effect on CD43 expression (Table 1) .
PMA did not affect surface expression of CD43 on lymphocytes (Fig. 1B) . In contrast, L-selectin expressed on these cells was down-regulated by the same treatment.
Anti-CD43 mAb-Induced Down-Regulation of CD43. Anti-CD44 mAb immobilized to a plastic surface via goat antimouse IgG has previously been shown to induce dramatic down-regulation of CD44 on both human lymphocytes and granulocytes (15) . Similarly, soluble anti-CD14 mAbs were shown to down-regulate CD14 on human monocytes (22) . To ask whether anti-CD43 mAb has a similar effect on CD43 surface expression, lymphocytes were incubated with an immobilized anti-CD43 mAb, MEM-59; strong downregulation of CD43 on these cells was induced ( Fig. 2A) . Analogously, immobilized MEM-59 also down-regulated CD43 on granulocytes, but only to a minimal extent (note, however, that the incubation of MEM-59 with lymphocytes was 12 h, but with granulocytes the incubation had to be limited to 3 h because of their rapid loss of viability; Fig. 2B ). Surface expression of CD45 antigen, used as a control, remained unchanged during incubation of both lymphocytes and granulocytes with immobilized MEM-59.
A mixture of soluble anti-CD43 mAbs had a downregulatory effect on lymphocyte CD43 expression similar to that obtained using the immobilized MEM-59 (Fig. 3) .
Identification of Soluble CD43 Cleaved from the Surface of Stimulated Cells. The mechanism responsible for downregulation of CD43 may involve (i) CD43 internalization, (ii) release of this protein from the cell surface to the medium, or (iii) a conformational alteration of CD43 that results in loss of the epitope(s) recognized by anti-CD43 mAb(s). To test the possibility that CD43 is released from the cell surface, surface-iodinated granulocytes (or lymphocytes) were stimulated with PMA (or the mixture of the soluble anti-CD43 mAbs that was able to down-regulate CD43 on lymphocytes; Fig. 3) . The supernatants obtained were tested for the presence of soluble CD43 (or soluble CD43-anti-CD43 mAb complexes, respectively). 125I-labeled soluble CD43 forms were detected in the supernatants of both PMA-activated granulocytes ( Fig. 4A ) and anti-CD43 mAb-stimulated lymphocytes (Fig. 4B ). Specific bands corresponding to 120, 60, and 47 kDa were found in the supernatant of PMA-activated granulocytes (Fig. 4A) , whereas specific bands corresponding to 120 and 84 kDa were present in the supernatant of anti-CD43 mAb-stimulated lymphocytes (Fig. 4B) . Thus, CD43 is released from the surface of stimulated cells into the medium.
The apparent size of the 120-kDa fragment released from these cells is only slightly smaller than intact CD43, despite the relatively large size of the cleaved transmembrane and cytoplasmic regions (11) . The released protein, however, was truly soluble and could not be sedimented by centrifugation.
Inhibition of CD43 Release by Enzyme Inhibitors. CD43 is a type I transmembrane glycoprotein on both granulocytes and lymphocytes. To ask whether a protease(s) is involved in its release from the cell surface, the effect of various protease inhibitors on PMA-stimulated CD43 down-regulation was tested. A panel of inhibitors included phosphoramidon, pepstatin A, a1-antitrypsin, N-methoxysuccinyl-Ala-Ala-ProVal chloromethyl ketone, 1,10-phenanthroline, TLCK, Pefabloc SC, and EDTA. The only inhibitors that significantly inhibited CD43 cleavage were 1,10-phenanthroline, TLCK, and Pefabloc SC (Fig. 5 ). EDTA had a very weak inhibitory effect, which was much less profound than that obtained with 1,10-phenanthroline. All other inhibitors tested had no effect on CD43 down-regulation (data not shown).
Comparison compared with Galgp by using SDS/PAGE. All of these molecules appeared identical (Fig. 6) . The 120-kDa product can obviously be further degraded when released from granulocytes or lymphocytes (see Fig. 4 ).
DISCUSSION
Here, stimulation of leukocytes is shown to induce loss of CD43 from the cell surface. CD43 is enzymatically cleaved from the surface of granulocytes in response to PMA since (i) labeled soluble CD43 can be isolated from the culture supernatant of these cells treated with PMA and (ii) protease inhibitors are able to block PMA-induced CD43 downregulation. A 120-kDa soluble form of CD43 was found in the supernatant of PMA-treated granulocytes. In some experiments, two additional bands corresponding to 60 and 47 kDa were also detected on autoradiograms. The intensities of these bands relative to the 120-kDa molecule were dependent on the conditions used for PMA treatment 3 . Down-regulation of CD43 induced by a mixture of soluble anti-CD43 mAbs. Lymphocytes were incubated in medium with a mixture of the anti-CD43 mAbs MEM-59, G10-2, G19-1, L66, and T2/53 (ascites diluted 1:500) at 4°C for 1 h. The cells were then extensively washed, resuspended in medium, and divided into two aliquots. The first aliquot of the cells (trace 1) was kept on ice, whereas the second aliquot (trace 2) was incubated at 37°C for 3 h. After treatment, cell surface expression of CD43 was measured by flow cytometry using the mixture of anti-CD43 mAbs. Note that the difference in time of incubation (3 h) as compared to that in Fig. 2A (12 h) results in incomplete loss of CD43 in this experiment.
cytes were treated with PMA in the presence of 10% fetal calf serum for 2.5 h, the 120-kDa protein was hardly detectable, while 60-and 47-kDa bands represented the major molecules (data not shown). In contrast, when a shorter time (1 h) was used for incubation of cells with PMA in the presence of a higher fetal calf serum concentration (30%), the yield of the 120-kDa protein was higher compared to the two other proteins. Therefore, the 60-and 47-kDa forms seem to represent proteolytic fragments of CD43. Recently, Campanero et al. (23) have described PMA-induced downregulation of CD43 on granulocytes that was blocked by the serine protease inhibitors phenylmethylsulfonyl fluoride and aprotinin. However, soluble CD43 was not detected in the culture supematant of these cells. In the present work, a serine protease was also implicated in CD43 cleavage from granulocytes since serine protease inhibitors TLCK and Pefabloc SC inhibited PMA-induced CD43 down-regulation. In addition, however, a metalloprotease also appears to participate in CD43 cleavage, since CD43 down-regulation was markedly inhibited by the metalloprotease inhibitor 1,10-phenanthroline (a heavy metal chelator), although it was not affected by EDTA. Strikingly, a zinc-dependent metalloprotease has been reported to be involved in cleavage of CD16 from natural killer cells (24) . The question of whether the same metalloprotease is involved in the cleavage of CD43 and CD16 remains to be clarified. The proteases involved in the induced CD43 cleavage must be endogenous cellular enzymes, since the same PMA-induced down-regulation of CD43 was observed even under serum-free conditions (data not shown), excluding the possibility that an exogenous protease present in fetal calf serum (used as a component of culture medium) cleaved membrane CD43. The observation that both serine protease inhibitors and the metalloprotease inhibitor 1,10-phenanthroline block CD43 down-regulation suggests that a protease cascade, including both a serine protease and a metalloprotease, is involved in CD43 cleavage. Cellular metalloproteases that are present in a latent inactive form and that can be activated by endogenous serine proteases after cell stimulation are known to be expressed by granulocytes (25) (26) (27) (28) . Thus, these enzymes may both participate in the induced cleavage of CD43 from stimulated granulocytes.
In this report, CD43 is also shown to be cleaved from the surface of stimulated lymphocytes. In contrast to granulo- 1: 500.) The cells were then extensively washed and divided into two aliquots. The first aliquot (-) was immediately lysed in lysis buffer while the second aliquot of cells (+) was incubated in medium at 37°C for 3 h. After incubation, cells were sedimented and lysed in lysis buffer. The supernatants (Sup) and the cell lysates (Cells) obtained were analyzed for the presence of CD43-anti-CD43 mAb complexes (or CD45-anti-CD45 mAb complexes) by means of the solid-phase immunoisolation technique using immobilized goat anti-mouse IgG, SDS/PAGE, and autoradiography. Note that the partial loss of CD43 from cells (lymphocytes) under these conditions (see Fig. 3 ) was evident in the original autoradiogram, but was not readily reproduced by photography. The further degradation of the 120-kDa product appears different in granulocytes and lymphocytes. In the latter (B), the 87-kDa product appears to be stable (see also Fig. 6, lane 2) , whereas in the former (A), the 60-and 47-kDa products could result from further degradation of the 87-kDa form or could be generated from the 120-kDa form by an independent mechanism. cytes, PMA was not able to induce CD43 cleavage from lymphocytes. Instead, crosslinking of surface CD43, mediated either by immobilized anti-CD43 mAb or by a mixture of soluble anti-CD43 mAbs, initiated its cleavage. A soluble CD43 of 120 kDa, the same size as the molecule solubilized from granulocytes, was found in the supernatant together with an additional protein of 84 kDa, which is very likely a second proteolytic CD43 fragment. The cleavage of CD43 from the surface of lymphocytes must also be mediated by a protease, since CD43 is expressed on these cells as a typical transmembrane protein. However, experiments testing the effect of protease inhibitors were technically impossible since lymphocyte incubations with inhibitors had to proceed over a long period of time (see Fig. 2A ) under which conditions the binding of irrelevant mAb is also affected by these reagents.
Recently, isolation and biochemical characterization of a human plasma galactoglycoprotein, termed Galgp, identical to the extracellular region of CD43, has been reported (11) . This glycoprotein is present in plasma in high concentrations (>10 ,ug/ml) (29) . The high galactose and N-acetylgalactosamine contents in the glycans of Galgp (17) due to a low effective concentration of ICAM-1 (caused, for example, by a conformational alteration of ICAM-1 attached to plastic). An alternative possibility is that a ligand different from ICAM-1 is required to initiate CD43 cleavage. Nevertheless, the fact that several other receptors, mostly adhesion molecules, including CD44 (15), L-selectin (30), and CD14 (22) , can also be enzymatically cleaved from leukocytes in response to antibody stimulation, which may mimic the effect of natural ligands, may indicate a more general significance of this mechanism.
What might be the physiological role of induced enzymatic cleavage of CD43 in vivo? The function of CD43 is still not fully understood. CD43, which is highly sialylated and thus renders a negative charge to the cell membrane, has been suggested to be involved in cell-cell repulsion (5) . It is conceivable that multiple sialic acid residues, modifying CD43, minimize nonspecific cellular interactions. Therefore, the loss of CD43 from leukocyte membrane could dramatically reduce the negative charge of the membrane, which might be accompanied by reduced intercellular repulsion. Indeed, during preparation of this manuscript, Rieu et al. (31) reported that shedding of CD43 from granulocytes correlated with their homotypic aggregation. Moreover, the loss of CD43 from the cell membrane could expose certain receptors (e.g., adhesion molecules), to allow specific cell-cell interactions to occur. Another possibility is that the induced loss of surface CD43 may be part of a regulatory mechanism controlling certain leukocyte effector functions (e.g., cell adhesion triggered via CD43). Finally, enzymatic cleavage of membrane CD43 might represent a mechanism responsible for in vivo production of soluble CD43/Galgp found in serum. In general, soluble forms of surface receptors have been proposed to have several functions. They may act as (i) inhibitors of interactions between membrane-bound receptors and their cell-bound ligands, as suggested for soluble ICAM-1 (32), or soluble ligands, as proposed for the TNF-a receptor (33) , (ii) mediators of interactions between ligands and other membrane receptors as demonstrated for soluble CD14 (34), or (iii) transporter molecules protecting the ligands delivered to their membrane receptors, as proposed for soluble forms of cytokine receptors (35) . So far, the physiological role of soluble CD43 remains unknown.
Thus, induced enzymatic cleavage of leukocyte receptors might represent a general mechanism regulating surface expression of these molecules. In addition to CD43, other receptors, including CD14 (22), CD44 (15), CD16 (36), L-selectin (37, 38) , CD23 (39), CD27 (40), CD32 (41) , and TNF receptor (42) , have been shown to be cleaved from the surface of stimulated leukocytes. However, many questions are still to be answered; for example, (i) which enzymes are involved in the cleavage, (ii) is there a universal enzyme responsible for cleavage of several receptors expressed on a certain leukocyte subpopulation or is there a group of enzymes that selectively cleave their target receptors, (iii) which amino acid sequences are attacked by these enzymes, (iv) what is the mechanism of enzymatic cleavage induction, and (v) which natural ligands are responsible for the receptor cleavage induction?
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